Cargando…

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program

Disclosure: J. Newell-Price: Consulting Fee; Self; HRA Pharmaceuticals, Diurnal, Novartis Pharmaceuticals, Recordati Rare Diseases, Crinetics. Grant Recipient; Self; Crinetics, Diurnal, HRA Pharmaceuticals, Novartis Pharmaceuticals, Recordati Rare Diseases. R. Pivonello: Consulting Fee; Self; Novart...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newell-Price, John, Pivonello, Rosario, Lacroix, André, Biller, Beverly M K, Feelders, Richard, Gadelha, Mônica, Bertherat, Jérôme, Belaya, Zhanna, Piacentini, Andrea, Pedroncelli, Alberto M, Fleseriu, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Neuroendocrinology And Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554774/ http://dx.doi.org/10.1210/jendso/bvad114.1118

Ejemplares similares

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE
por: Marin, Luis Madera, et al.
Publicado: (2022)

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function
por: Minasyan, Mari, et al.
Publicado: (2023)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension
por: Gadelha, Mônica, et al.
Publicado: (2023)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

THU021 Mysterious Resolution Of Cushing’s Disease
por: Whiteman, Daniel R, et al.
Publicado: (2023)

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
por: Gadelha, Mônica, et al.
Publicado: (2022)

THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN
por: Isand, Kristina, et al.
Publicado: (2023)

THU009 Subclinical Cushing’s Syndrome In An ACTH-secreting Pituitary Macroadenoma
por: Akabogu, Nwamaka Gloria, et al.
Publicado: (2023)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

THU040 Different Patient Versus Provider Perspectives On Living With Cushing’s Disease
por: Halstrom, Amanda, et al.
Publicado: (2023)

THU039 Use Of Desmopressin In The Differential Diagnosis Of Cushing’s Syndrome: Recent Experience At The NIH
por: McGlotten, Raven, et al.
Publicado: (2023)

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide
por: Samson, Susan Leanne, et al.
Publicado: (2023)

THU081 Differences In Circulating Microrna Levels In Genetically Confirmed Multiple Endocrine Neoplasia Type 1 And Multiple Endocrine Neoplasia Type 1 Phenocopies As Assessed By Next Generation Sequencing
por: Trukhina, Diana A, et al.
Publicado: (2023)

THU108 Pituitary Carcinoma Diagnosed After Ten Years Of Smoldering Ectopic Nasopharyngeal Cushing’s
por: Carafone, Lindsay, et al.
Publicado: (2023)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

THU034 Severe Obesity In Cushing´s Disease In A Tertiary Center: Current Prevalence And Diagnostic Implications
por: Mascarenhas-Nakano, Bruna Maria Grosso, et al.
Publicado: (2023)

THU016 Hiding In Plain Sight: Florid Cushing’s Disease Presenting As A Severe Extremity Cellulitis
por: Godar, Cassandra M, et al.
Publicado: (2023)

THU013 A Rare Case of Ectopic Cushing’s Syndrome Caused By Metastatic Parotid Gland Carcinoma
por: Punni, Emma, et al.
Publicado: (2023)

THU011 Cushing’s Disease Diagnosis Challenge With Standard Pituitary MRI: A Clinical Case Report
por: Kasiri, Elnaz, et al.
Publicado: (2023)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

THU031 White Blood Cells (WBC) As Biological Markers Of Cortisol Status In Patients With Cushing's Disease (CD)
por: Mascarenhas-Nakano, Bruna Maria Grosso, et al.
Publicado: (2023)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

THU036 (68)Ga-DOTATOC PET/CT In Localization Of ACTH-producing Pituitary Tumors In Patients With Cushing Disease
por: Kim, Kyungwon
Publicado: (2023)

THU020 Bilateral Adrenal Hyperplasia (BAH): Undesirable Effect Of Glucocorticoid Receptor Competitive Antagonist (GRCAnt) In Cushing’s Disease
por: Canturk, Ayse, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9m2h0tngvf3bgkvam7q1stcsme